A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
This phase II trial studies how well talimogene laherparepvec works and nivolumab in treating
patients with lymphomas that do not responded to treatment or non-melanoma skin cancers that
have spread to other places in the body or do not responded to treatment. Biological
therapies, such as talimogene laherparepvec, use substances made from living organisms that
may stimulate or suppress the immune system in different ways and stop tumor cells from
growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body''s
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread. Giving talimogene laherparepvec and nivolumab may work better in treating
patients with lymphomas or non-melanoma skin cancers.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.